Early Encouraging UC Davis Trial Data on Cell Therapy for Spina Bifida

Key Takeaways

• Six fetuses treated with placental MSCs showed intact repairs.
• No cerebrospinal fluid leaks or tumor formation observed.
• MRIs indicated reversal of hindbrain herniation post‑treatment.
• Larger trial of 29 patients approved for statistical validation.

Summary

A first‑in‑human phase 1 trial at UC Davis evaluated placental mesenchymal stem cells delivered intra‑uterinely to fetuses with myelomeningocele. Six pregnancies treated between June 2021 and December 2022 resulted in intact repair sites, no cerebrospinal fluid leaks, infections, or tumor formation, and MRI scans showed reversal of hindbrain herniation. The study demonstrated early safety signals and suggests potential efficacy for this complex cell‑therapy approach. Researchers have secured approval for a larger, 29‑patient trial to confirm long‑term outcomes.

Pulse Analysis

Spina bifida, particularly the myelomeningocele form, remains one of the most severe congenital neural tube defects, often leading to lifelong mobility challenges and costly medical care. Traditional postnatal surgery addresses the physical defect but cannot fully prevent secondary brain malformations such as hindbrain herniation. As prenatal diagnostics improve, the medical community has turned to in‑utero interventions, hoping to modify disease trajectory before irreversible damage occurs. The promise of stem‑cell therapy lies in its ability to promote tissue regeneration and modulate inflammation directly at the lesion site, a concept that could revolutionize fetal surgery.

The UC Davis CuRe trial represents a pivotal step in translating this concept to humans. Researchers harvested mesenchymal stem cells from placental tissue, expanded them under GMP conditions, and injected them into the defect during fetoscopic surgery at 24–25 weeks gestation. All six infants were delivered preterm but survived, displaying intact repair sites without cerebrospinal fluid leaks, infection, or abnormal tissue growth. Follow‑up MRIs revealed a striking reversal of hindbrain herniation, suggesting that the cellular graft may support neural tissue remodeling. These early safety and efficacy signals are especially compelling given the procedural complexity of fetal surgery compared with more routine intravenous MSC applications.

Looking ahead, the approved expansion to a 29‑patient cohort will provide the statistical power needed to assess functional outcomes such as motor development and cognitive performance. Success could accelerate regulatory pathways for fetal regenerative medicines and attract investment from biotech firms seeking to diversify their pipelines. However, challenges remain, including scaling cell manufacturing, ensuring consistent surgical expertise, and monitoring long‑term safety. If the larger trial confirms these initial findings, prenatal MSC therapy could become a new standard for spina bifida, reshaping both clinical practice and the market for advanced fetal therapeutics.